Open Access

Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment

Viviana Frantellizzi

Viviana Frantellizzi

Department of Molecular Medicine, Sapienza University of RomeRome, Italy
Search for this author on
Sciendo|Google Scholar
Frantellizzi, Viviana
, 
Arianna Pani

Arianna Pani

Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan “Statale”Milan, Italy
Search for this author on
Sciendo|Google Scholar
Pani, Arianna
, 
Maria Dea Ippoliti

Maria Dea Ippoliti

Department of Radiological Sciences, Oncology and Anatomical Pathology , Sapienza University of RomeRome, Italy
Search for this author on
Sciendo|Google Scholar
Ippoliti, Maria Dea
, 
Alessio Farcomeni

Alessio Farcomeni

Department of Public Health and Infectious Diseases, “Sapienza” University of RomeRome, Italy
Search for this author on
Sciendo|Google Scholar
Farcomeni, Alessio
, 
Irvin Aloise

Irvin Aloise

Department of Computer, Control, and Management Engineering Antonio Ruberti, Sapienza University of RomeRome, Italy
Search for this author on
Sciendo|Google Scholar
Aloise, Irvin
, 
Mirco Colosi

Mirco Colosi

Department of Computer, Control, and Management Engineering Antonio Ruberti, Sapienza University of RomeRome, Italy
Search for this author on
Sciendo|Google Scholar
Colosi, Mirco
, 
Claudia Polito

Claudia Polito

Specialty School in Medical Physics, Department of Medico-Surgical Sciences and Biotechnologies, University La SapienzaRome, Italy
Search for this author on
Sciendo|Google Scholar
Polito, Claudia
, 
Roberto Pani

Roberto Pani

Specialty School in Medical Physics, Department of Medico-Surgical Sciences and Biotechnologies, University La SapienzaRome, Italy
Search for this author on
Sciendo|Google Scholar
Pani, Roberto
 and 
Giuseppe De Vincentis

Giuseppe De Vincentis

Department of Radiological Sciences, Oncology and Anatomical Pathology , Sapienza University of RomeRome, Italy
Search for this author on
Sciendo|Google Scholar
Vincentis, Giuseppe De
  
Dec 19, 2019
Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment's Cover Image
About this article
Previous Article
Next Article
Cite
Download Cover
Article Category: Research Article
Published Online: Dec 19, 2019
Page range: 40 - 47
Received: Jun 18, 2019
Accepted: Oct 22, 2019
DOI: https://doi.org/10.2478/raon-2019-0058
Keywords
© 2020 Viviana Frantellizzi, Arianna Pani, Maria Dea Ippoliti, Alessio Farcomeni, Irvin Aloise, Mirco Colosi, Claudia Polito, Roberto Pani, Giuseppe De Vincentis, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Patient of our cohort with bone metastases analyzed with DASciS software. Bone scan index (BSI) value = 5.26%.
Patient of our cohort with bone metastases analyzed with DASciS software. Bone scan index (BSI) value = 5.26%.

Figure 2

Kaplan-Meier curve for overall survival.
Kaplan-Meier curve for overall survival.

Figure 3

Bone scan index (BSI) over time.0 = baseline bone scan; 2–3 = bone scan after 2 and 3 cycles of Ra-223 therapy; 6 = bone scan after treatment’s end; 9 - 12 - 24 = follow-up scintigraphic image study respectively after 3 months, 6 months and 1.5 year from the end of the treatment
Bone scan index (BSI) over time.0 = baseline bone scan; 2–3 = bone scan after 2 and 3 cycles of Ra-223 therapy; 6 = bone scan after treatment’s end; 9 - 12 - 24 = follow-up scintigraphic image study respectively after 3 months, 6 months and 1.5 year from the end of the treatment

Figure 4

ROC curve of overall survival (OS) prediction for a score based on combining bone scan index (BSI) and 3-PS (AUC 91%).
ROC curve of overall survival (OS) prediction for a score based on combining bone scan index (BSI) and 3-PS (AUC 91%).

Figure 5

99mTc-HMDP Bone scan, example of evaluation of load of the disease. (A) Few but very extensive bone metastases. Bone scan index (BSI) value = 6.13%. (B) numerous but small bone metastases. BSI value = 3.4%.
99mTc-HMDP Bone scan, example of evaluation of load of the disease. (A) Few but very extensive bone metastases. Bone scan index (BSI) value = 6.13%. (B) numerous but small bone metastases. BSI value = 3.4%.

Univariate and multivariable analysis of overall survival (OS) in relation to baseline variables

Clinical covariatesUnivariate HR (95% models CI)p-valueMultivariable HR (95% CI) modelp-value
BSI1.80 (1.61–2.02)< 0.0011.79 (1.59–2.01)< 0.001
Age (years)1.02 (0.99–1.05)0.184
BMI0.94 (0.89–1.00)0.057
Gleason Score0.97 (0.91–1.04)0.414
ECOG Performance Status1.97 (1.48–2.64)< 0.0011.74 (1.29–2.36)< 0.001
N of previous systemic treatments1.35 (1.12–1.164)0.002
Baseline Hb0.73 (0.64–0.84)< 0.001
Baseline PLT / 1001.51 (1.19–1.92)< 0.001
Baseline PSA / 1001.06 (1.02–1.12)0.006
Baseline tALP /1001.11 (1.06–1.17)< 0.001

Expected survival for baseline bone scan index (BSI) intervals

% BSIPatients number (n = 127)Median survival (months)0.95 LowCL (months)0.95 UpCL (months)
0–3592819NA
3–53311912
> 535557

Baseline patients’ characteristics

Baseline variablePatients (n = 127)%
Age (years)
Mean (range)73.82 (59–90)
Heigth (m)
Mean (range)1.71 (1.58–1.95)
Weight (kg)
Mean (range)78.60 (59–120)
BMI
Mean (range)26.75 (19.57–39.18)
Gleason score
Mean (range)6.3 (5–10)
510.79
632.36
73829.92
83023.62
92822.04
1021.59
Unknown2519.68
ECOG Performance status
Mean (range)0.86 (0–3)
03930.7
16853.54
2–32015.75
Extent of skeletal disease
< 6 metastases1814.17
6–20 metastases4636.22
> 20 metastases6349.61
No. of previous systemic treatments after
castration resistance (Docetaxel, Cabazitaxel,
Abiraterone, Enzalutamide)
03225.19
14233.07
23225.19
≥ 32116.53
No. of therapy’s cycles administered
Mean (range)5.56 (2–6)
232.36
332.36
4107.87
51411.02
69776.38
No. of systemic treatments after Radium223
Docetaxel118.6
Cabazitaxel00
Abiraterone21.5
Enzalutamide64.7
Baseline Hb
Median (range)12.14 (7.5–15)
< 12 g/dl5442.51
≥ 12 g/dl7357.48
Baseline tALP*
Median (range)300 (34–1750)
< 226 U/l7962.2
≥ 226 U/l4887.8
Baseline PLT (103/mm3)
Median (range)249 (74–763)
Baseline PSA
< 20 ng/ml4233.07
≥ 20 ng/ml8566.92
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed